Astellas receives European approval for XTANDI TM (enzalutamide) in adult men with high-risk non metastatic castration resistant prostate cancer.
More information can be read in the press release (PDF)
Extended reimbursement conditions of Inlyta® (axitinib) in advanced RCC (stage IV).
Since March 1st 2020 axitinib is reimbursed in combination with avelumab or pembrolizumab for the 1st line treatment of adult patients with advanced RCC (stage IV).
Each product of the combination needs a separate e-Health request by a medical oncologist or a urologist with special competences in oncology.
All details of the reimbursement criteria can be found on www.riziv.be
For more information on INLYTA® , please read the Summary of Product Characteristics available at: http://notices.fagg-afmps.be
200475 May 2020